Functional characterization of alpha(1)-adrenoceptor subtypes in human subcutaneous resistance arteries

Jarajapu, Y. P.R., Johnston, F., Berry, C. , Renwick, A., McGrath, J. C. , MacDonald, A. and Hillier, C. (2001) Functional characterization of alpha(1)-adrenoceptor subtypes in human subcutaneous resistance arteries. Journal of Pharmacology and Experimental Therapeutics, 299(2), pp. 729-734. (PMID:11602687)

Full text not currently available from Enlighten.

Publisher's URL:


The functional characteristics of the α1-adrenoceptor subtypes in human resistance arteries are still not clear. We recently reported that the α1A-adrenoceptor predominantly mediates contraction to norepinephrine in human skeletal muscle resistance arteries. In this study we extended these investigations to human subcutaneous resistance arteries. Arterial segments were isolated from the inguinal subcutaneous fat and mounted on a small vessel wire myograph. Potencies of agonists and antagonists were examined.N-[5-(4,5-dihydro-1H-imidazol-2yl)-2-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl]methanesulphonamide (A-61603) was found to be 10- and 54-fold more potent than norepinephrine and phenylephrine, respectively. Brimonidine (UK 14304) evoked significantly smaller contractile responses than norepinephrine and phenylephrine, showing the presence of a small population of α2-adrenoceptors in these arteries, and this was confirmed by the studies with selective α1- and α2-adrenoceptor antagonists prazosin and (8aR,12aS,13aS)-5,8,8a,9,10,11,12,12a,13a-decahydro-3-methoxyl-12-(ethylsulphonyl)-6H-isoquino[2,1-g][1,6]-naphthyridine (RS 79948). Prazosin, 5-methyl-urapidil, and 2-[2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane (WB 4101) shifted the potency of norepinephrine concentration dependently giving pA2 values of 9.4, 8.9, and 10.1, respectively, showing the presence of the α1A-subtype in these arteries. Pretreatment with 1 and 10 μM chloroethylclonidine did not affect the potency of and maximum responses to norepinephrine, ruling out the presence of the α1B-subtype in these arteries. 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (BMY 7378, 10 and 100 nM) did not affect the potency of norepinephrine but a small shift was observed by 1 μM BMY 7378, giving a pKB value of 7.1, much less than that reported for the α1D-subtype. These results suggest the predominant involvement of α1A-adrenoceptor in the contractile responses to norepinephrine in these arteries. The physiological role of this subtype in the maintenance of peripheral arterial resistance is yet to be confirmed.

Item Type:Articles
Glasgow Author(s) Enlighten ID:Berry, Professor Colin and McGrath, Professor John
Authors: Jarajapu, Y. P.R., Johnston, F., Berry, C., Renwick, A., McGrath, J. C., MacDonald, A., and Hillier, C.
College/School:College of Medical Veterinary and Life Sciences > School of Cardiovascular & Metabolic Health
College of Medical Veterinary and Life Sciences > School of Life Sciences
Journal Name:Journal of Pharmacology and Experimental Therapeutics
Publisher:American Society for Pharmacology and Experimental Therapeutics
ISSN (Online):1521-0103

University Staff: Request a correction | Enlighten Editors: Update this record